1. The effect of galanin on baseline and GHRH-induced growth hormone secretion in obese children.
- Author
-
Loche S, Pintus S, Cella SG, Boghen M, Vannelli S, Benso L, Müller EE, Corda R, and Pintor C
- Subjects
- Child, Drug Synergism, Female, Galanin, Growth Hormone blood, Humans, Male, Neuropeptides physiology, Peptides physiology, Growth Hormone metabolism, Growth Hormone-Releasing Hormone pharmacology, Neuropeptides pharmacology, Obesity metabolism, Peptides pharmacology
- Abstract
We have evaluated the effect of the administration of galanin (Gal), a newly identified hypothalamic peptide, on baseline and GHRH-induced GH rise in five obese children and in seven controls. The GH response to GHRH (hpGRF(1-29), 1 microgram/kg i.v.), and to Gal (15 micrograms/kg/h for 1 h), evaluated both as the maximum GH peak and as integrated area under the curve (AUC), was significantly lower in the obese children than in the controls. Simultaneous administration of Gal plus GHRH significantly increased the GH response to GHRH in all the obese subjects, so that their mean peak GH levels and AUC after Gal plus GHRH were similar to those of the control children after GHRH. Also, in control children Gal caused a significant augmentation of the GH response to GHRH. Mean peak GH levels and mean AUC after Gal plus GHRH were significantly higher in the controls than in the obese children given the same treatment. Our data indicate that obese children have a blunted GH response to Gal, which, however, is able to enhance the GH response to GHRH. This observation strengthens the view that the mechanism of action of Gal involves modulation of endogenous somatostatin (SRIH) release. In addition, similarity between the effects of Gal and pyridostigmine on baseline and GHRH-stimulated GH release in obese children may indicate the existence of a cholinergic link in the action of Gal.
- Published
- 1990
- Full Text
- View/download PDF